Details for Patent: 6,303,103
✉ Email this page to a colleague
Title: | Aerosols containing salmeterol xinafoate and an anticholinergic medicament |
Abstract: | This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described. |
Inventor(s): | Akehurst; Rachel Ann (Ware, GB), Taylor; Anthony James (Ware, GB), Wyatt; David Andrew (Ware, GB) |
Assignee: | Glaxo Group Limited (Greenford, GB) |
Filing Date: | Jun 14, 2000 |
Application Number: | 09/593,380 |
Claims: | 1. A pharmaceutical aerosol formulation which consists essentially of particulate medicament which is salmeterol xinafoate and an anticholinergic medicament in combination and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant based on the weight of the medicament. 2. A pharmaceutical aerosol formulation which consists of particulate medicament which is salmeterol xinafoate and an anticholinergic medicament in combination and 1,1,1,2-tetrafluoroethane as propellant. 3. A formulation as claimed in claim 1 wherein the anticholinergic medicament is selected from the list consisting of ipatropium, atropine, oxitropium and salts thereof. 4. A formulation as claimed in claim 2 wherein the anticholinergic medicament is selected from the list consisting of ipatropium, atropine, oxitropium and salts thereof. 5. A formulation as claimed in claim 3 wherein the anticholinergic medicament is ipratropium or a salt thereof. 6. A formulation as claimed in claim 4 wherein the anticholinergic medicament is ipratropium or a salt thereof. 7. A formulation according to claim 1 wherein the medicament is present in an amount of 0.1 to 1% w/w based on the weight of formulation. 8. A formulation according to claim 2 wherein the medicament is present in an amount of 0.1 to 1% w/w based on the weight of formulation. 9. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 1. 10. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 2. 11. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 5. 12. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 6. 13. A pharmaceutical aerosol formulation which consists essentially of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and an anticholinergic medicament in combination and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant. |